AR031374A1 - FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING - Google Patents

FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING

Info

Publication number
AR031374A1
AR031374A1 ARP010100556A ARP010100556A AR031374A1 AR 031374 A1 AR031374 A1 AR 031374A1 AR P010100556 A ARP010100556 A AR P010100556A AR P010100556 A ARP010100556 A AR P010100556A AR 031374 A1 AR031374 A1 AR 031374A1
Authority
AR
Argentina
Prior art keywords
dosage form
agonist
released
opiaceo
formulation
Prior art date
Application number
ARP010100556A
Other languages
Spanish (es)
Inventor
Benjamin Oshlack
Curtis Wright
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Priority to ARP010100556A priority Critical patent/AR031374A1/en
Publication of AR031374A1 publication Critical patent/AR031374A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revela una forma de dosificacion oral caracterizado por (i) un agonista opiáceo en forma liberable y (ii) un antagonista opiáceo secuestrado sustancialmente no liberado cuando la forma de dosificacion se administra intacta, tal que la relacion de la cantidad de antagonistas liberado de dicha forma de dosificacion después de la alteracion a la cantidad de dicho antagonista liberado de dicha forma de dosificacion intacta es de aproximadamente 4:1 o mayor, basado sobre la disolucion in-vitro después de 1 hora de dicha forma de dosificacion entre 900 ml de Fluido Gástrico Simulado utilizando un aparato USP tipo II (paleta) a 75 rpm a 37 degree C en donde dicho agonista y antagonista se dispersan a través de la forma de dosificacion y no se encuentran aislados uno de otro en dos capas diferentes.An oral dosage form is revealed characterized by (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonists released from said Dosage form after alteration to the amount of said antagonist released from said intact dosage form is approximately 4: 1 or greater, based on the in-vitro solution after 1 hour of said dosage form between 900 ml of Fluid Gastric Simulated using a USP type II device (paddle) at 75 rpm at 37 degree C where said agonist and antagonist are dispersed through the dosage form and are not isolated from each other in two different layers.

ARP010100556A 2001-02-07 2001-02-07 FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING AR031374A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP010100556A AR031374A1 (en) 2001-02-07 2001-02-07 FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP010100556A AR031374A1 (en) 2001-02-07 2001-02-07 FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING

Publications (1)

Publication Number Publication Date
AR031374A1 true AR031374A1 (en) 2003-09-24

Family

ID=37516039

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100556A AR031374A1 (en) 2001-02-07 2001-02-07 FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING

Country Status (1)

Country Link
AR (1) AR031374A1 (en)

Similar Documents

Publication Publication Date Title
YU58902A (en) Tamper-resistant oral opioid agonist formulations
CO5640086A2 (en) OPIOID AGONIST FORMULATION WITH LIBERABLE AND SEQUESTED ANTAGONISTS
CR6458A (en) VALDECOXIB COMPOSITIONS
EE04096B1 (en) Pharmaceutical compositions containing selected lanthanum carbonate hydrates
CO5611096A2 (en) PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL ADMINISTRATION
KR880009634A (en) Improving Pseudoephedrine Bromfeniramine Therapy
ES2185395T3 (en) ORAL LIQUID MUCOADHESIVE COMPOSITIONS.
UY27296A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MOSAPRIDE AND PANCREATIN
AR033221A1 (en) PHARMACEUTICAL COMPOSITION FINALLY SELF-EMULSIONABLE
ID28510A (en) NEW ORAL FORMULATION FOR AGONISTS OR 5-HT4 ANTAGONISTS
BR0212155A (en) Pharmaceutical Composition
BRPI0412430A (en) zot and zonulin receptor agonist polypeptide
UY27644A1 (en) OSMOTE SUPPLY SYSTEM
CO5200833A1 (en) DOSAGE REGIMES FOR LASOFOXIFENO
AR031374A1 (en) FORMULATION AGONIST ORAL OPIACEO RESISTANT TO HANDLING
ECSP066274A (en) SAQUINAVIR MESILATO, ORAL DOSAGE FORM
BRPI0413374A (en) weak base release compositions for an extended period of time
PE20040670A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING AMBROXOL AND ISOPROPAMIDE IODIDE
AR044004A1 (en) PHARMACEUTICAL FORMULATION BY ORAL ROUTE FOR ANTAGONIST AGENTS OF PROTON PUMPS
KR870009716A (en) Chlorfeniramine Formulation
DE50005282D1 (en) MEDICINE AND MATCHED COMBINATION OF MEDICINES
TR200301552A1 (en) Novel oral pharmacological formulations of rofecoxib.
RU2002112882A (en) A method of increasing the resistance of dry cows
TH32076B (en) Size form of pharmaceutical rubber for oral administration containing proton pulling inhibitors. And prokinetic substances
TH102688A (en) Pharmaceutical components for accelerating salivation and the use of this substance.

Legal Events

Date Code Title Description
FB Suspension of granting procedure